This presentation is about Peptic Ulcer Disease. I presented it in 2017 to my colleagues at Al Ain hospital. Information provided is up to date. I allow you to use it for educational purposes.
This presentation is about Peptic Ulcer Disease. I presented it in 2017 to my colleagues at Al Ain hospital. Information provided is up to date. I allow you to use it for educational purposes.
Ulcers are the areas of degeneration and necrosis of gastro intestinal mucosa exposed to acid of the alimentary tract that is exposed to hydrochloric acid and pepsin they occur most commonly (98-99%) in either the duodenum or the stomach in the ratio 4:1
Gastroesophageal Reflux Disease (GERD) is a common disorder that has undergone many paradigm changes in the last 15 years. We discuss the current paradigms in the pathophysiology, diagnosis and management of GERD.
Ulcers are the areas of degeneration and necrosis of gastro intestinal mucosa exposed to acid of the alimentary tract that is exposed to hydrochloric acid and pepsin they occur most commonly (98-99%) in either the duodenum or the stomach in the ratio 4:1
Gastroesophageal Reflux Disease (GERD) is a common disorder that has undergone many paradigm changes in the last 15 years. We discuss the current paradigms in the pathophysiology, diagnosis and management of GERD.
Omni-directional Vision and 3D Animation Based Teleoperation of Hydraulically Actuated Hexapod Robot COMET-IV
H. Ohroku and K. Nonami
Graduate School of Science and Technology, Chiba University, 1-33 Yayoi-cho, Inage-ku, Chiba-shi, Chiba, 263-8522, Japan
Intelligent e-assessment: ontological model for personalizing assessment activities
Rafaela Blanca Silva-López1, Iris Iddaly Méndez-Gurrola1, Victor Germán Sánchez Arias2
1 Universidad Autónoma Metropolitana, Unidad Azcapotzalco.
Av. San Pablo 180, Col. Reynosa Tamaulipas, Del. Azcapotzalco, México, D.F.
2 Universidad Nacional Autónoma de México
Circuito Escolar Ciudad Universitaria, 04510 México, D.F.
Please join us on Fridays in Paltlak room Bayt al-Arqam for explanation and discussion of the topic every Friday. Check RevolutionMuslim.com for the exact date and time, inshallah
A circumscribed ulceration of the GI mucosa occurring in areas exposed to acid and pepsin with a defect in the mucosa that extends through the
Muscularis mucosa into the
Submucosa or deeper.
Gastrointestinal Diseases
Group 5:
Leticia Bernal Leon
Daydig Rodriguez
Maria Rodriguez
Karina Silveira
Instructor:
Dr. Alain Llanes Rojas, DNP, APRN, FNP-BC
Miami Regional University
Diagnosis, Symptoms & Illness Management
MSN5600
Gastroesophageal Reflux
Gastroesophageal reflux that does not cause symptoms is known as physiologic reflux. In nonerosive reflux disease (NERD), individuals have symptoms of reflux disease but no visible or minimal esophageal mucosal injury
Gastroesophageal reflux disease (GERD) is the reflux of acid and pepsin or bile salts from the stomach to the esophagus that causes esophagitis. The severity of the esophagitis depends on the composition of the gastric contents and esophageal mucosa exposure time.
Definition & Classification
Gastroesophageal Reflux
Causes
GERD can be caused by abnormalities or alterations in
1. Lower esophageal sphincter function
2. Esophageal motility
3. Gastric motility or emptying
Esophageal function studies include the following:
Determination of the lower esophageal sphincter (LES) pressure (manometry)
Graphic recording of esophageal swallowing waves, or swallowing pattern (manometry)
Detection of reflux of gastric acid back into the esophagus (acid reflux)
Detection of the ability of the esophagus to clear acid (acid clearing)
An attempt to reproduce symptoms of heartburn (Bernstein test)
Gastroesophageal Reflux
Risk Factors
Obesity
Hiatal hernia
Use of drugs or chemicals that relax the LES (anticholinergics, nitrates, calcium channel blockers, nicotine)
Cigarette smoke.
Trigger Factors
Coughing
Vomiting
Straining at stool
Asthma
Chronic cough
Sinusitis.
Gastroesophageal Reflux
Common Symptoms
Heartburn that occurs 30 to 60 minutes after meals and when the patient bends over or lies down.
Regurgitation of sour or bitter gastric contents
Belching, and fullness of the stomach
Upper abdominal pain within 1 hour of eating.
Atypical Symptoms
chronic cough
asthma attacks
chronic laryngitis
sinusitis
discomfort during swallowing.
Noncardiac chest pain.
Dysphagia
Gastroesophageal Reflux
Clinical manifestations are related to mucosal injury from acid regurgitation and the frequency and duration of reflux events.
The symptoms worsen if the individual lies down or if intraabdominal pressure increases because of coughing, vomiting, or straining at stool.
Uncomplicated GERD that is responsive to first-line therapy does not require an endoscopy.
Patients who do not respond to therapy and those with suspected complications should undergo an endoscopic examination
Management & Evaluation
Differential diagnosis
Gastritis
Peptic ulcer
Gastric cancer
Cholelithiasis
Angina pectoris.
Gastroesophageal Reflux
Diagnosis of GERD is based on the history and clinical manifestations.
An upper endoscopy with biopsy is the standard diagnostic procedure for GERD. It confirms the diagnosis and documents the type and extent of tissue damage.
Esophageal endoscopy: shows hyperemia ...
Model Attribute Check Company Auto PropertyCeline George
In Odoo, the multi-company feature allows you to manage multiple companies within a single Odoo database instance. Each company can have its own configurations while still sharing common resources such as products, customers, and suppliers.
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdfTechSoup
In this webinar you will learn how your organization can access TechSoup's wide variety of product discount and donation programs. From hardware to software, we'll give you a tour of the tools available to help your nonprofit with productivity, collaboration, financial management, donor tracking, security, and more.
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...Levi Shapiro
Letter from the Congress of the United States regarding Anti-Semitism sent June 3rd to MIT President Sally Kornbluth, MIT Corp Chair, Mark Gorenberg
Dear Dr. Kornbluth and Mr. Gorenberg,
The US House of Representatives is deeply concerned by ongoing and pervasive acts of antisemitic
harassment and intimidation at the Massachusetts Institute of Technology (MIT). Failing to act decisively to ensure a safe learning environment for all students would be a grave dereliction of your responsibilities as President of MIT and Chair of the MIT Corporation.
This Congress will not stand idly by and allow an environment hostile to Jewish students to persist. The House believes that your institution is in violation of Title VI of the Civil Rights Act, and the inability or
unwillingness to rectify this violation through action requires accountability.
Postsecondary education is a unique opportunity for students to learn and have their ideas and beliefs challenged. However, universities receiving hundreds of millions of federal funds annually have denied
students that opportunity and have been hijacked to become venues for the promotion of terrorism, antisemitic harassment and intimidation, unlawful encampments, and in some cases, assaults and riots.
The House of Representatives will not countenance the use of federal funds to indoctrinate students into hateful, antisemitic, anti-American supporters of terrorism. Investigations into campus antisemitism by the Committee on Education and the Workforce and the Committee on Ways and Means have been expanded into a Congress-wide probe across all relevant jurisdictions to address this national crisis. The undersigned Committees will conduct oversight into the use of federal funds at MIT and its learning environment under authorities granted to each Committee.
• The Committee on Education and the Workforce has been investigating your institution since December 7, 2023. The Committee has broad jurisdiction over postsecondary education, including its compliance with Title VI of the Civil Rights Act, campus safety concerns over disruptions to the learning environment, and the awarding of federal student aid under the Higher Education Act.
• The Committee on Oversight and Accountability is investigating the sources of funding and other support flowing to groups espousing pro-Hamas propaganda and engaged in antisemitic harassment and intimidation of students. The Committee on Oversight and Accountability is the principal oversight committee of the US House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X.
• The Committee on Ways and Means has been investigating several universities since November 15, 2023, when the Committee held a hearing entitled From Ivory Towers to Dark Corners: Investigating the Nexus Between Antisemitism, Tax-Exempt Universities, and Terror Financing. The Committee followed the hearing with letters to those institutions on January 10, 202
A Strategic Approach: GenAI in EducationPeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Safalta Digital marketing institute in Noida, provide complete applications that encompass a huge range of virtual advertising and marketing additives, which includes search engine optimization, virtual communication advertising, pay-per-click on marketing, content material advertising, internet analytics, and greater. These university courses are designed for students who possess a comprehensive understanding of virtual marketing strategies and attributes.Safalta Digital Marketing Institute in Noida is a first choice for young individuals or students who are looking to start their careers in the field of digital advertising. The institute gives specialized courses designed and certification.
for beginners, providing thorough training in areas such as SEO, digital communication marketing, and PPC training in Noida. After finishing the program, students receive the certifications recognised by top different universitie, setting a strong foundation for a successful career in digital marketing.
Read| The latest issue of The Challenger is here! We are thrilled to announce that our school paper has qualified for the NATIONAL SCHOOLS PRESS CONFERENCE (NSPC) 2024. Thank you for your unwavering support and trust. Dive into the stories that made us stand out!
Biological screening of herbal drugs: Introduction and Need for
Phyto-Pharmacological Screening, New Strategies for evaluating
Natural Products, In vitro evaluation techniques for Antioxidants, Antimicrobial and Anticancer drugs. In vivo evaluation techniques
for Anti-inflammatory, Antiulcer, Anticancer, Wound healing, Antidiabetic, Hepatoprotective, Cardio protective, Diuretics and
Antifertility, Toxicity studies as per OECD guidelines
2024.06.01 Introducing a competency framework for languag learning materials ...Sandy Millin
http://sandymillin.wordpress.com/iateflwebinar2024
Published classroom materials form the basis of syllabuses, drive teacher professional development, and have a potentially huge influence on learners, teachers and education systems. All teachers also create their own materials, whether a few sentences on a blackboard, a highly-structured fully-realised online course, or anything in between. Despite this, the knowledge and skills needed to create effective language learning materials are rarely part of teacher training, and are mostly learnt by trial and error.
Knowledge and skills frameworks, generally called competency frameworks, for ELT teachers, trainers and managers have existed for a few years now. However, until I created one for my MA dissertation, there wasn’t one drawing together what we need to know and do to be able to effectively produce language learning materials.
This webinar will introduce you to my framework, highlighting the key competencies I identified from my research. It will also show how anybody involved in language teaching (any language, not just English!), teacher training, managing schools or developing language learning materials can benefit from using the framework.
A Survey of Techniques for Maximizing LLM Performance.pptx
APD Presentation by Prof.Javed Akram
1.
2. New Perspectives in The Management of Peptic
Ulcer Disease.
Professor Javed Akram.
Mb, MEE(Can), MRCP(UK), FRCP(Glasg), FRCP(Edin), FRCP(London),
FACP(USA), FASIM(USA), FACC(USA).
3. Peptic Ulcer Disease
A peptic ulcer is a break (an ulceration) in
the protective mucous lining (mucosa) of
the lower esophagus, stomach or duodenum
4. Common Misconceptions
A peptic ulcer is NOT:
A stress ulcer
Chronic gastritis (a symptom as well as a disease state
that may lead to peptic ulcers)
Dyspepsia (the symptoms that may or may not be
diagnosed as an ulcer)
Peptic Ulcers cannot be diagnosed solely on the
basis of clinical presentation (Werdmuller et al.
1996)
6. Dyspepsia - Definition
A group of symptoms which alert
clinicians to consider disease of the upper
gastrointestinal tract
(British Society of Gastroenterology, 1996)(British Society of Gastroenterology, 1996)
7. Symptoms of Functional Dyspepsia
NocturnalNocturnal
painpain
LocalizedLocalized
epigastricepigastric
burningburning
BetterBetter
with foodwith food
HeartburnHeartburn
RetrosternalRetrosternal
burningburning
NauseaNausea
BloatingBloating
Early satietyEarly satiety
WorseWorse
with foodwith food
Ulcer-like DominantUlcer-like Dominant Dysmotility-like DominantDysmotility-like Dominant
8. Quick Stats:Peptic Ulcer
5-10% lifetime incidence
1-2% of people have ulcer at any given time
$5.65 billion industry
10. Types
Gastric
Slightly more common in men and way more
common in elderly
Most commonly located in the stomach’s lesser
curvature, antrum
1-3% associated with gastric carcinomas
Basic defect is disruption of gastric mucosal
barrier (gastritis, duodenal reflux, H. pylori,
NSAIDS)
11. Types
Duodenal
Almost always located in the duodenal bulb
More likely culprit in chronic disease
No association with cancer
12.
13.
14. Risk Factors
Smoking
33-100% more likely to develop duodenal ulcers
Retards healing of identified ulcers
J Akram& Colleagues ..E.J.of Gastrenterology.Nov2003)
Age and Sex
Alcohol
Diet
Milk
Stress
Ramadan fasting
15. Risk Factors
NSAIDS
Responsible for majority of ulcers not caused
by H.pylori
Greater risk for complications once ulcer
identified
Risk of GU increases sixfold when taking
>three aspirin/day. Buffered coat has no
advantage
16. Prevalence of Endoscopic
NSAID-Induced Ulceration
Mean Range
Gastric Ulcer 15 % 10 to 30%
Duodenal Ulcer 5 % 4 to 10 %
Clinically Significant Ulcers 2% 1 to 4%
17. Risk Factors for
Serious GI Adverse Events with NSAIDs: Relative Risks
Rodriguez. Lancet. 1994; Guttham. Epidemiology. 1997; Shorr. Arch Intern Med.
1993; Piper. Ann Intern Med. 1991.
0 5 10 15
4.4 (2.0-9.7)
12.7 (6.3-25.7)
2.9 (2.2-3.8)
5.8 (4.0-8.6)
5.6 (4.6-6.9)
3.1 (2.5-3.7)
1.6 (1.4-2.0)
13.5 (10.3-17.7)
Corticosteroid use
Anticoagulant use
Low dose NSAIDLow dose NSAID
High dose NSAID
Age 70-80
Age 60-69
Age 50-59
Prior bleed
Relative RiskRelative Risk
19. Peptic Ulcers and Stress
Experimental stress results in decreased
upper gastrointestinal blood flow in animals
(Kauffman, 1997; Livingston 1993)
Effect of stress seems to be reversible
(Levenstein et al., 1996)
20. Peptic Ulcer and Personality
Studies have found a strong association
between dependency and peptic ulcers
Patients with peptic ulcer have significantly
more personality disturbances than control
subjects (Feldman et al.)
Ulcer patients also more inclined to
pessimism and excessive dependence
(Akram et al.)
21.
22. Helicobacter pylori
Gram-negative spiral organism
Most common and important risk factor for
duodenal ulcer
Variable risk factor for gastric ulcers
10% healthy people under 30, 60% healthy
people over 60.
Will cause disease in 15-20% of infected
Eradication is the key
24. Diagnosis
Vague discomfort and feeling of gnawing hunger
Duodenal usually has predictable food relationship (1-3 hrs after meal)
Gastric ulcer relationship with food more variable
Gastric ulcer-weight loss
Duodenal ulcer-weight gain
Watch for peptic ulceration/bleeding: melena, radiation of pain to
back/shoulder
26. Studies
Radiography
Barium swallow with double contrast
Duodenal-detects 40-80%
Gastric-detects 65-80%
Endoscopy
Gold standard
Detects up to 95% gastroduodenal ulcers
Generally considered the study of choice esp. for
large ulcers or those not clearly benign
27. Diagnosis of H. pylori
Invasive (if patient requires endoscopy)
Histologic testing (50-90% sensitive, 100%
specific)
Rapid urease (CLO) test (95% sensitive and
95% specific)*
Noninvasive
IgG antibody*
Urea breath test (96% sensitive, 98% specific)
30. A common medical condition
250,000 – 500,000 admissions/year in US
UGI bleeding incidence 100/100,000 adults
Incidence increases 20-30 fold from third to
ninth decade of life
GI bleeding stops spontaneously in 80 %
32. Therapy
Goal is to heal the ulcer and prevent
recurrence
Both can be accomplished by eradicating H.
pylori if present
Treat the acute pain if necessary
33. Nonpharmacologic
There is no evidence that dietary modifications
changes the course of the disease
Quit smoking
Milk intake
Faster healing, lower recurrence, lower
complications
Discontinue NSAIDS
COX2 Inhibitors?
34. Treatment of ulcers
Eradicate H. pylori
Single antibiotic therapy does not work
Compliance is key
More than 60% of the doses must be taken to ensure
eradication
If eradicated, maintenance therapy not needed. If
recurs, check for H. pylori again
If H. pylori not found, check again and treat with H2-
receptor antagonists, PPI’s and sucralfate
Document healing of gastric ulcers with endoscopy
38. PHAMACOKINETICSPHAMACOKINETICS
ABS0RPTION
Minimal absorption by GIT 3-5%
ABS0RPTION
Minimal absorption by GIT 3-5%
EXCRETION
Approximately 90% is excreted in the stool, very
small amount is excreted in the urine.
EXCRETION
Approximately 90% is excreted in the stool, very
small amount is excreted in the urine.
39. INDICATIONS OF ULCOCID
Duodenal ulcers
Gastric ulcers
treatment of reflux and peptic oesophagitis
H.pylori
treatment of NSAID & aspirin induced GI symptoms and
mucosal damage.
Prevention of stress ulcers and GI bleeding in critically ill
patients.
Treatment of oral and oesophageal ulcers due to radiation
chemotherapy & sclerotherapy.
Sucralfate enemas in ulcerative colitis & colonic
carcinomas
Duodenal ulcers
Gastric ulcers
treatment of reflux and peptic oesophagitis
H.pylori
treatment of NSAID & aspirin induced GI symptoms and
mucosal damage.
Prevention of stress ulcers and GI bleeding in critically ill
patients.
Treatment of oral and oesophageal ulcers due to radiation
chemotherapy & sclerotherapy.
Sucralfate enemas in ulcerative colitis & colonic
carcinomas
40. AVAILABILITY OF DRUG
1. ULCOCID tablets
( containing 500 mg Sucralfate per tablet ).
2. ULCOCID tablets
( containing 1 g Sucralfate per tablet ).
3. ULCOCID Susp. 60 ml
( containing 1 g Sucralfate per 5ml).
1. ULCOCID tablets
( containing 500 mg Sucralfate per tablet ).
2. ULCOCID tablets
( containing 1 g Sucralfate per tablet ).
3. ULCOCID Susp. 60 ml
( containing 1 g Sucralfate per 5ml).
41. DOSAGE RECOMMENDATION OF ULCOCID
For Ulcer Patients
Morning
2g Ulcocid
Evening
For Non Ulcer Patients
Morning
1 g Ulcocid
Evening
For Ulcer Patients
Morning
2g Ulcocid
Evening
For Non Ulcer Patients
Morning
1 g Ulcocid
Evening
42. ULCOCID
ULCOCID should always be
taken 1 hour before meals at
bed time (Monotherapy)
Do not take antacids 1/2 hour
before or after taking
ULCOCID (Polytherapy).
ULCOCID should always be
taken 1 hour before meals at
bed time (Monotherapy)
Do not take antacids 1/2 hour
before or after taking
ULCOCID (Polytherapy).
43. ANTACIDS Vs ULCOCD
ANTACIDS
Just symptomatic therapy.
Intense antacid regimen required
for healing.
Not safe for hypertensive or
cardiac patients.
Non-Palatable.
Not suitable for working class
because of frequent dose taken.
ANTACIDS
Just symptomatic therapy.
Intense antacid regimen required
for healing.
Not safe for hypertensive or
cardiac patients.
Non-Palatable.
Not suitable for working class
because of frequent dose taken.
ULCOCID
Ulcer healing occurs.
None
Palatable
Dosage is convenient.
ULCOCID
Ulcer healing occurs.
None
Palatable
Dosage is convenient.
44. Ulcocid Vs H2- Receptor AntagonistsUlcocid Vs H2- Receptor Antagonists
Ulcocid
Less side effects
Can be administered to elderly.
Smokers can use it.
Does not effect hepatic
metabolism of drugs.
Does not effect pulmonary
functions in patients with pre-
existing broncho- pulmonary
diseases.
Ulcocid
Less side effects
Can be administered to elderly.
Smokers can use it.
Does not effect hepatic
metabolism of drugs.
Does not effect pulmonary
functions in patients with pre-
existing broncho- pulmonary
diseases.
H2-Receptor Antagonists
More side effects
Causes hallucination and delirium
in elderly
Only for non- smokers.
Does effect the metabolism of
drugs metabolized by Cytochrome
P-450 path-way.
H2 – blockers may worsen the
condition.
H2-Receptor Antagonists
More side effects
Causes hallucination and delirium
in elderly
Only for non- smokers.
Does effect the metabolism of
drugs metabolized by Cytochrome
P-450 path-way.
H2 – blockers may worsen the
condition.
45. Human Studies.Human Studies.
Comparative evaluation of Sucralfate &
Cimetidine efficacy in treatment of chronic
erosive gastritis.
The results of patients with chronic erosive
gastritis treated with Sucralfate &
Cimetidine were compared. The result of
examinations indicate that chronic erosive
gastritis is difficult to be heal; Sucralfate
proved to be more efficient than
Cimetidine.
Ref: Au:Kula-Z:Walasek-L So:Pizegl-Lek 1998; 51(2): 73-6
Comparative evaluation of Sucralfate &
Cimetidine efficacy in treatment of chronic
erosive gastritis.
The results of patients with chronic erosive
gastritis treated with Sucralfate &
Cimetidine were compared. The result of
examinations indicate that chronic erosive
gastritis is difficult to be heal; Sucralfate
proved to be more efficient than
Cimetidine.
Ref: Au:Kula-Z:Walasek-L So:Pizegl-Lek 1998; 51(2): 73-6
46. Meta-analysis:Human Studies.Meta-analysis:Human Studies.
Comparative evaluation of Sucralfate &
Cimetidine efficiency in treatment of
chronic erosive gastritis proved that
Sucralfate is more efficient than
Cimetidine.
Ref: Au: Kula-Z:Walasek-L So:Pizegl-Lek 1999; 51(2): 73-6
Comparative evaluation of Sucralfate &
Cimetidine efficiency in treatment of
chronic erosive gastritis proved that
Sucralfate is more efficient than
Cimetidine.
Ref: Au: Kula-Z:Walasek-L So:Pizegl-Lek 1999; 51(2): 73-6
47. ULCOCID Vs ACID PUMP
INHIBITORS
ULCOCID Vs ACID PUMP
INHIBITORS
Acid Pump Inhibitors
Jaundice has been reported.
Hypoglycaemia, Wt. Gain.
Increased intragastric
concentrations of viable
bacteria during the T/M.
Acid Pump Inhibitors
Jaundice has been reported.
Hypoglycaemia, Wt. Gain.
Increased intragastric
concentrations of viable
bacteria during the T/M.
Ulcocid
No jaundice reported
None
None
Ulcocid
No jaundice reported
None
None
48. Anti Helicobacter effects
Omeprazole Vs Ulcocid
(With Clarithromycin and Metronidazole)
75
80
85
90
95
100
4 Weeks
Healing
H.Pylori
eradication
Omeprazole
Ulcocid
50. HUMAN AND ANIMAL STUDIES
Invitro and clinical data suggest that triple
therapy with SUCRALFATE is effective in
eradicating HELICOBACTER PYLORI and
reducing duodenal ulcer relapse.
Ref: Louw- Ja So:Scand-J-Gastroenterol-Suppl. 1998; 191:28-31
Invitro and clinical data suggest that triple
therapy with SUCRALFATE is effective in
eradicating HELICOBACTER PYLORI and
reducing duodenal ulcer relapse.
Ref: Louw- Ja So:Scand-J-Gastroenterol-Suppl. 1998; 191:28-31
51. Human StudiesHuman Studies
Glycosulfatase activity of H. Pylori towards human
gastric mucin; effect of Sucrafate.
Results demonstrate that H. Pylori, through its Glycosulfatase
activity affects the sulphated mucin & glycero-gluco-lipid
content of the protective mucous layer & that anti-ulcer
drug Sucralfate is able to counteract the detrimental action
of this enzyme.
Ref: Slomiany-BL; Piotrowski-J; Grabska-M; SLOMIANY-a So: Am-j-
Gastroenterol. 1999 Sep; 87(9); 1132-7
Glycosulfatase activity of H. Pylori towards human
gastric mucin; effect of Sucrafate.
Results demonstrate that H. Pylori, through its Glycosulfatase
activity affects the sulphated mucin & glycero-gluco-lipid
content of the protective mucous layer & that anti-ulcer
drug Sucralfate is able to counteract the detrimental action
of this enzyme.
Ref: Slomiany-BL; Piotrowski-J; Grabska-M; SLOMIANY-a So: Am-j-
Gastroenterol. 1999 Sep; 87(9); 1132-7
52. ULCOCID INHIBITS THE EFFECT OF
H.Pylori on gastric mucins
ULCOCID INHIBITS THE EFFECT OF
H.Pylori on gastric mucins
0
200
400
600
800
1000
1200
Specific binding (dpm/assay)
Control 10 40 80
ULCOCID (mg/ml)
53. ULCOCID
Direct binding to ulcer
crater
Stimulates prostaglandin
production
Enhances the surface
active phospholipid
mucosal barrier.
Stimulates growth factors
. Epidermal
. Transforming
. Fibroblast
Anti-helicobacter effects.
58. HUMAN STUDIESHUMAN STUDIES
Management of bleeding in a patient with
colorectal cancer:
SUCRALFATE an oral cytoprotective, used
topically in a patient with colo-rectal cancer
resulting in control of bleeding, less
localized pain and more freedom &
independence for the patient.
Ref: Au: Famcombe-M So: Support-care-cancer, 1993 May;1(3):159-60.
Management of bleeding in a patient with
colorectal cancer:
SUCRALFATE an oral cytoprotective, used
topically in a patient with colo-rectal cancer
resulting in control of bleeding, less
localized pain and more freedom &
independence for the patient.
Ref: Au: Famcombe-M So: Support-care-cancer, 1993 May;1(3):159-60.
59. WHY ULCOCID ?WHY ULCOCID ?
Fast pain relief.
Excellent healing rate.
Equal good for smokers and non - smokers.
Good for elderly.
Equally good for ulcer and non - ulcer
patients.
Economical
Fast pain relief.
Excellent healing rate.
Equal good for smokers and non - smokers.
Good for elderly.
Equally good for ulcer and non - ulcer
patients.
Economical